ArticleFrontiers in pharmacology2025
Half-dose may be equivalent to full-dose anticoagulants in preventing venous thromboembolism after primary total joint arthroplasty: a single center comparative retrospective cohort study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal anticoagulant administration for deep vein thrombosis (DVT) prevention following total joint arthroplasty (TJA) remains controversial. We aimed to compare the effectiveness and safeness of half-dose and full-dose anticoagulant regimen in preventing DVT following TJA surgery. Methods: This study was designed as a retrospective comparative analysis. All eligible patients received DVT prophylaxis within 2 weeks postoperatively, consisting of enoxaparin (first 2 days) and rivaroxaban (subsequent 12 days). According to the dosage of anticoagulant, patients were divided into a half-dose group (0.2 mL enoxaparin sodium and 5 mg rivaroxaban) and a full-dose DVT prophylaxis group (0.4 mL enoxaparin sodium and 10 mg rivaroxaban). The occurrence of DVT and pulmonary thromboembolism (PE) within 2 weeks postoperative, total blood loss (TBL) during the use of anticoagulants. WOMAC scores recorded at 12 months postoperative were compared between the two groups. Results: A total of 1886 patients were enrolled in this study, including 1,246 in the half-dose group and 640 in the full-dose group. No cases of PE were reported in the two groups. The DVT was detected in 11 patients (0.9%) in the half-dose group, which was not significantly different from 8 patients (1.3%) in the full-dose group, p = 0.648. Also, the WOMAC scores were comparable between the half-dose group (11.11 ± 18.01) and the full-dose group (8.88 ± 15.33), p = 0.393. Contrastively, the TBL (560.88 ± 307.69 mL) and average hospital stay (4.73 ± 1.50 days) were significantly lower in the half-dose group than that in the full-dose group (653.95 ± 333.70 mL, 5.74 ± 2.36 days), p < 0.001. Conclusion: Half-dose of DVT prophylaxis drugs during the perioperative period of TJA does not elevate DVT incidence. Furthermore, it significantly decreases TBL and shortens hospital stays, while having no adverse impact on postoperative joint function recovery. These findings may support the implementation of half-dose protocol anticoagulants in the TJA protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.